Potential Weakness in SARS-CoV-2 Discovered – Single Protein Needed for COVID-19 Virus to Reproduce and Spread

Beating COVID-19 Coronavirus

Revealed: The Secrets our Clients Used to Earn $3 Billion

A single protein that appears essential for the COVID-19 infection to recreate and infect other cells is a prospective weak point that might be targeted by future treatments.

The particle, called transmembrane protein 41 B (TMEM41B), is thought to assist form the fatty external membrane that safeguards the infection’ hereditary product while it duplicates inside a contaminated cell and prior to it contaminates another.

The newest finding originates from a set of research studies led by scientists at NYU Grossman School of Medicine and NYU Langone Health’s Perlmutter Cancer Center, and coworkers at Rockefeller University and in other places.

Published in the journal Cell online December 8, 2020, the research studies exposed that TMEM41B was important for SARS-CoV-2 to duplicate. In a series of experiments, scientists compared how the COVID-19 infection recreates in contaminated cells to the exact same procedures in 2 lots fatal flaviviruses, consisting of those accountable for yellow fever, West Nile, and Zika illness. They likewise compared how it recreates in contaminated cells to 3 other seasonal coronaviruses understood to trigger the acute rhinitis.

“Together, our studies represent the first evidence of transmembrane protein 41 B as a critical factor for infection by flaviviruses and, remarkably, for coronaviruses, such as SARS-CoV-2, as well,” states the research studies’ co-senior detective John T. Poirier, PhD.

“An important first step in confronting a new contagion like COVID-19 is to map the molecular landscape to see what possible targets you have to fight it,” states Poirier, an assistant teacher of medication at NYU Langone Health. “Comparing a newly discovered virus to other known viruses can reveal shared liabilities, which we hope serve as a catalog of potential vulnerabilities for future outbreaks.”

“While inhibiting transmembrane protein 41 B is currently a top contender for future therapies to stop coronavirus infection, our results identified over a hundred other proteins that could also be investigated as potential drug targets,” states Poirier, who likewise acts as director of the Preclinical Therapeutics Program at NYU Langone and Perlmutter Cancer Center.

For the research studies, scientists utilized the gene-editing tool CRISPR to suspend each of more than 19,000 genes in human cells contaminated with each infection, consisting of SARS-CoV-2. They then compared the molecular results of each shutdown on the infection’ capability to duplicate.

In addition to TMEM41B, some 127 other molecular functions were discovered to be shared amongst SARS-CoV-2 and other coronaviruses. These consisted of typical biological responses, or paths, associated with cell development, cell-to-cell interaction, and indicates by which cells bind to other cells. However, scientists state, TMEM41B was the only molecular function that stood apart amongst both households of infections studied.

Interestingly, Poirier notes, anomalies, or modifications, in TMEM41B are understood to be typical in one in 5 East Asians, however not in Europeans or Africans. He warns, nevertheless, that it is prematurely to inform if this discusses the fairly out of proportion seriousness of COVID-19 health problem amongst some populations in the United States and in other places. Another research study finding was that cells with these anomalies were more than 50 percent less prone to flavivirus infection than those without any gene anomaly.

Poirier states more research study is required to identify if TMEM41B anomalies straight give defense versus COVID-19 and if East Asians with the anomaly are less susceptible to the illness.

The research study group next strategies to draw up TMEM41B’s accurate function in SARS-CoV-2 duplication so they can begin screening treatment prospects that might obstruct it. The group likewise has strategies to study the other typical paths for comparable prospective drug targets.

Poirier includes that the research study group’s success in utilizing CRISPR to map the molecular weak points in SARS-CoV-2 acts as a design for researchers worldwide for challenging future viral break outs.


“TMEM41B IS A PAN-FLAVIVIRUS HOST FACTOR” by H.-Heinrich Hoffmann, William M. Schneider, Kathryn Rozen-Gagnon, Linde A. Miles, Felix Schuster, Brandon Razooky, Eliana Jacobson, Xianfang Wu, Soon Yi, Charles M. Rudin, Margaret R. MacDonald, Laura K. McMullan, John T. Poirier and Charles M. Rice, 8 December 2020, Cell.
DOI: 10.1016/j.cell.2020.12.005

“Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks” by William M. Schneider, Joseph M. Luna, H.-Heinrich Hoffmann, Francisco J. Sánchez-Rivera, Andrew A. Leal, Alison W. Ashbrook, Jérémie Le Pen, Inna Ricardo-Lax, Eleftherios Michailidis, Avery Peace, Ansgar F. Stenzel, Scott W. Lowe, Margaret R. MacDonald, Charles M. Rice and John T. Poirier, 9 December 2020, Cell.
DOI: 10.1016/j.cell.2020.12.006

Study financing was offered by National Institutes of Health grants R01 AI091707, U19 AI111825, R01 CA190261, R01 CA213448, U01 CA2133359, R01 AI143295, R01 AI150275, R01 AI124690, R01 AI116943, P01 AI138938, P30 CA008748, P30 CA016087, R03 AI141855, R21 AI142010, T32 CA160001. Additional financing assistance was offered by the G. Harold and Leila Y. Mathers Charitable Foundation, the BAWD Foundation, and Fast Grants.

Besides Poirier, another NYU Langone scientist associated with these research studies is Andrew Leal. Other partners consisted of research study co-senior detective Charles Rice and research study co-investigators William Schneider, Joseph Luna, Heinrich Hoffman, Alison Ashbrook, Jeremie Le Pen, Inna Ricardo-Lax, Eleftherios Michailidis, Avery Peace, Ansgar Stenzel, Margaret MacDonald, Kathryn Rozen-Gagnon, Felix Schuster, Brandon Razooky, Eliana Jacobson, Xianfang Wu, and Soon Yi, at Rockefeller University in New York City; Francisco-Sanchez-Rivera, Scott Lowe, Linda Miles, and Charles Rudin, at Memorial Sloan Kettering Cancer Center in New York City; and Laura McMullen, at the U.S. Centers for Disease Control and Prevention in Atlanta.

This site uses Akismet to reduce spam. Learn how your comment data is processed.